EMEric B. Milbrandt

Eric B. Milbrandt

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Eric B. Milbrandt has a total of 8 co-authors. Here are the top co-authors by number of shared publications:

  • Ajay D. Rao

    Section of Endocrinology, Diabetes, and Metabolism (A.D.R.), Lewis Katz School of Medicine at Temple University, Philadelphia, PA

    1 shared publication
  • Derek C. Angus

    University of Pittsburgh, Pittsburgh, PA

    1 shared publication
  • John A. Kellum

    Center for Critical Care Nephrology, Department of Critical Care Medicine, University of Pittsburgh, Pittsburgh, USA

    1 shared publication
  • Lan Kong

    From the CRISMA Laboratory (Clinical Research, Investigation, and Systems Modeling of Acute Illness) (SY, EBM, JAK, RLD, DCA), Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA; and the Department of Biostatistics (LK, LAW), University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA

    1 shared publication
  • Lisa A. Weissfeld

    Department of Biostatistics, University of Pittsburgh Pittsburgh, PA, USA

    1 shared publication
  • Russell L. Delude

    From the CRISMA Laboratory (Clinical Research, Investigation, and Systems Modeling of Acute Illness) (SY, EBM, JAK, RLD, DCA), Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA; and the Department of Biostatistics (LK, LAW), University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA

    1 shared publication

Latest Publications

  • Understanding the potential role of statins in pneumonia and sepsis*

    by Sachin Yende, Eric B. Milbrandt, John A. Kellum, Lan Kong, Russell L. Delude, Lisa A. Weissfeld, Derek C. Angus

    Objective: To examine the association of statin use with clinical outcomes and circulating biomarkers in community-acquired pneumonia and sepsis. Design: Multicenter inception cohort study. Setting: Emergency departments of 28 U.S. hospitals. Patients: A total of 1895 subjects hospitalized with community-acquired pneumonia. Interventions: None. Measurements and Main Results: Our approach consisted of two different comparison cohorts, each reflecting methods used in prior publications in this area. We first compared subjects with prior statin use (prior use cohort), defined as a history of statin use in the week before admission, with those with no prior use. We then compared prior statin users whose statins were continued inhospital (continued use cohort) with those with either no prior use or no inhospital use. We adjusted for patient characteristics, including demographics, comorbid conditions, and illness severity, and accounted for healthy user effect and indication bias using propensity analysis. We determined risk of severe sepsis and 90-day mortality. We measured markers inflammation (tumor necrosis factor, interleukin-6, interleukin-10), coagulation (antithrombin, factor IX, plasminogen activator inhibitor, d-dimer, thrombin antithrombin complex), and lymphocyte cell surface protein expression during the first week of hospitalization. There were no differences in severe sepsis risk between statin users and nonusers for prior (30.8% vs. 30.7%, p = .98) or continued statin use (30.2% vs. 30.8%, p = .85) in univariate analyses and after adjusting for patient characteristics and propensity for statin use. Ninety-day mortality was similar in prior statin users (9.2% vs. 12.0%, p = .11) and lower in continued statin users (7.9% vs. 12.1%, p = .02). After adjusting for patient characteristics and propensity for statin use, there was no mortality benefit for prior (odds ratio, 0.90 [0.63–1.29]; p = .57) or continued statin use (odds ratio, 0.73 [0.47–1.13]; p = .15). Only antithrombin activity over time was higher in statin subjects, yet the magnitude of the difference was modest. There were no differences in other coagulation, inflammatory, or lymphocyte cell surface markers. Conclusions: We found no evidence of a protective effect for statin use on clinical outcomes and only modest differences in circulating biomarkers in community-acquired pneumonia, perhaps as a result of healthy user effects and indication bias.


  • Open Access

    To JUPITER and beyond: Statins, inflammation, and primary prevention

    by Ajay D Rao, Eric B Milbrandt